{"id":"NCT03107377","sponsor":"Evofem Inc.","briefTitle":"Phase 2B/3 Double-blinded Placebo-controlled","officialTitle":"Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-11-03","primaryCompletion":"2019-08-22","completion":"2019-08-22","firstPosted":"2017-04-11","resultsPosted":"2020-08-12","lastUpdate":"2020-08-12"},"enrollment":860,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Chlamydia Trachomatis Infection"],"interventions":[{"type":"DRUG","name":"EVO100","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"EVO100","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection","primaryOutcome":{"measure":"Urogenital CT Infection","timeFrame":"16 weeks","effectByArm":[{"arm":"EVO100","deltaMin":14,"sd":null},{"arm":"Placebo","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0256"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":["33705748"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":376},"commonTop":["Bacterial Vaginosis","Vulvovaginal Candidiasis","Urinary tract infections","Vaginal Discharge","Vulvovaginal discomfort"]}}